• Axsome Therapeutics reported a Q3 EPS of -$1.34, surpassing the estimated -$1.38.
• The company's Q3 revenue reached approximately $104.8 million, exceeding estimates and marking an 81% year-over-year growth.
• Despite positive earnings and revenue growth, Axsome faces profitability challenges with a net loss of $64.6 million for the quarter.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative treatments, including AXS-07 for migraines and AXS-05 for Alzheimer's agitation. Despite its promising pipeline, Axsome faces competition from major pharmaceutical companies, which adds pressure to its financial performance.

On November 12, 2024, Axsome reported its Q3 earnings, revealing an EPS of -$1.34, which was better than the estimated -$1.38. This marks a slight increase from the -$1.32 EPS reported in the same quarter last year. The company achieved an earnings surprise of 2.90%, continuing its trend of surpassing consensus EPS estimates over the past four quarters.

Axsome's revenue for the quarter was approximately $104.8 million, surpassing the estimated $98.1 million and marking an 81% year-over-year growth. This performance exceeded the Zacks Consensus Estimate by 6.13%. The company has consistently outperformed consensus revenue estimates in each of the last four quarters, reflecting strong sales growth.

Despite these positive results, Axsome's path to profitability remains challenging. The company reported a net loss of $64.6 million for the quarter, highlighting substantial cash burn. Axsome's negative P/E ratio of -16.16 and negative earnings yield of -6.19% indicate ongoing profitability challenges. The enterprise value to operating cash flow ratio is also negative at -36.77, underscoring difficulties in generating positive cash flow.

Axsome's financial health is further illustrated by its debt-to-equity ratio of 2.06, indicating significant reliance on debt financing. However, the company maintains a strong current ratio of 2.44, suggesting it can cover short-term liabilities with its short-term assets. As Axsome anticipates FDA approval for AXS-07 in January, the potential for these treatments to achieve significant revenue remains uncertain.